Guillain‐barré Syndrome in Elderly People

Leung, Siu N.

doi:10.1111/j.1532-5415.2007.01516.x

Cited by 4 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGIV has an established safety profile in children and adults. Elderly subjects are treated with IGIV for both labeled and unlabeled conditions [1] , [14] ; however, there are limited data available from appropriately placebo-controlled, double-blinded studies on the safety of IGIV in elderly patients, with most data derived from case studies and retrospective studies [15] , [16] , [17] , [18] , [19] . IGIV has been associated with uncommon but serious adverse events (SAEs) for which the elderly carry an increased risk such as thrombotic events, transfusion-related lung injury (TRALI), and renal failure.…”

Section: Introductionmentioning

confidence: 99%

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long‐term, placebo‐controlled study of Alzheimer's disease

Gelmont

Thomas

Britt

et al. 2016

A&D Transl Res & Clin Interv

View full text Add to dashboard Cite

IntroductionWe present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease.MethodsThis was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0.25% human albumin (n = 121) administered every 2 weeks ± 7 days for 18 months.ResultsElevated risk ratios of IGIV versus placebo included chills (3.85) in 9.5% of IGIV-treated subjects (all doses), compared to 2.5% of placebo-treated subjects, and rash (3.08) in 15.3% of IGIV-treated subjects versus 5.0% of subjects treated with placebo. Subjects in the highest IGIV dose group had the lowest proportion of SAEs considered related to product (2 of 127 [1.6%]). Subjects treated with IGIV experienced a lower rate of respiratory and all other infections compared to placebo.DiscussionIGIV-treated subjects did not experience higher rates of renal failure, lung injury, or thrombotic events than the placebo group. There were no unexpected safety findings. IGIV was well tolerated throughout 18 months of treatment in subjects aged 50–89 years.

show abstract